Abstract. Ovarian cancer (OVCA) is the most lethal gynecological malignancy. The high mortality rate associated with this disease is due in large part to the development of resistance to chemotherapy; however, the biological basis of this remains unclear. Gemcitabine is frequently used for the treatment of patients with platinum-resistant OVCA. We report molecular signaling pathways associated with OVCA response to gemcitabine. Forty-one OVCA cell lines were subjected to gene expression analysis; in parallel, IC 50 values for gemcitabine were quantified using CellTiter-Blue viability assays. Pearson's correlation coefficients were calculated for gene expression and gemcitabine IC 50 values. The genes associated with gemcitabine sensitivity were subjected to pathway analysis. For the identified pathways, principal component analysis was used to derive pathway signatures and corresponding scores, which represent overall measures of pathway expression. Expression levels of the identified pathways were then evaluated in a series of clinicogenomic datasets from 142 patients with stage III/IV serous OVCA. We found that in vitro gemcitabine sensitivity was associated with expression of 131 genes (p<0.001). These genes include significant representation of three molecular signaling pathways (p<0.02): O-glycan biosynthesis, Role of Nek in cell cycle regulation and Antiviral actions of Interferons. In an external clinico-genomic OVCA dataset (n=142), expression of the O-glycan pathway was associated with overall survival, independent of surgical cytoreductive status, grade and age (p<0.001). Expression levels of Role of Nek in cell cycle regulation and Antiviral actions of Interferons were not associated with survival (p=0.31 and p=0.54, respectively). Collectively, expression of the O-glycan biosynthesis pathway, which modifies protein function via post-translational carbohydrate binding, is independently associated with overall survival from OVCA. Our findings shed light on the molecular basis of OVCA responsiveness to gemcitabine and also identify a signaling pathway that may influence patient survival.
Introduction
Ovarian cancer (OVCA) is the leading cause of gynecologic cancer mortality and the sixth most common cancer diagnosed in women in the United States. Advanced-stage epithelial OVCA is highly heterogeneous at a clinical, biologic, and genetic level, but patients are currently treated in a uniform fashion with cytoreductive surgery and platinum/taxane-based combination chemotherapy. Unfortunately, most patients ultimately succumb to persistent or recurrent platinum-resistant disease (1, 2) . Currently, efforts to develop therapeutic agents with greater efficacy against platinum-resistant disease are limited because of an incomplete understanding of the molecular determinants of OVCA drug response.
Gemcitabine (2',2'-difluorodeoxycytidine), a synthetic nucleoside analog of cytidine, is frequently used as a second-line therapy for patients with relapsed OVCA (3) . As a pyrimidine analogue, gemcitabine replaces the nucleic acid cytidine during DNA replication, blocking processing and chain elongation by the DNA polymerase complex, resulting in G1 arrest and a subsequent cytostatic effect. Additionally, the gemcitabine triphosphate metabolite is incorporated into RNA, thus inhibiting RNA synthesis (4) . Gemcitabine efficacy has been evaluated extensively both in vitro and in vivo against OVCA (5) (6) (7) (8) . Gemcitabine has demonstrated single-agent activity against OVCA cell lines (9) and synergistic activity with several other antineoplastic agents, including platinum compounds, topotecan, and etoposide (10) . In animal tumor models, the gemcitabine effect has been shown to be schedule dependent, and continuous infusions over 24 h
The O-glycan pathway is associated with in vitro sensitivity to gemcitabine and overall survival from ovarian cancer , JESUS GONZALEZ-BOSQUET 1, 4 , ROBERT M. WENHAM 1, 2, 4 , SACHIN M. APTE 1, 4 appear to enhance gemcitabine cytotoxicity (11) . Phase II and III studies of gemcitabine (800-1250 mg/m 2 /week) in patients with recurrent OVCA have demonstrated response rates up to 19% (12) (13) (14) . Despite such data, the molecular determinants of gemcitabine activity remain to be fully elucidated. In this study, we sought to determine the molecular underpinnings of OVCA response to gemcitabine at a genome-wide level. We investigated the genes and molecular signaling pathways associated with the response of OVCA cells in vitro to gemcitabine and explored how these pathways influence in vivo clinical outcomes for patients with this disease.
Materials and methods
Overview. We subjected 41 OVCA cell lines to gene expression analysis and, in parallel, measured gemcitabine sensitivity (IC 50 ). Genes associated with baseline gemcitabine sensitivity, identified by Pearson's correlation analysis, were subjected to molecular pathway analysis. We evaluated expression of identified pathways using a series of clinico-genomic datasets from 142 patients with stage III/IV serous OVCA. All 142 patients had signed IRB-approved, written informed consent forms. Durham, NC (A2008, C13, CAOV2, HeyA8, IGR-OV1, IMCC3,  IMCC5, MCAS, OV2008, OVCA420, OVCA429, OVCA432,  OVCA433, FUOV1, PEO1, PEO4, SK-OV-6, T8, TOV-112D,  TOV-21-G, Dov13, BG1, Ovary1847, OVCAR10, OVCAR8,  OVCAR5, OVCAR4, OVCAR2, SK-OV-4) . Cell lines were maintained in RPMI-1640 medium (Invitrogen, Carlsbad, CA) supplemented with 10% fetal bovine serum (Fisher Scientific, Pittsburgh, PA), 1% sodium pyruvate, 1% penicillin/streptomycin (Cellgro, Manassas, VA), and 1% non-essential amino acids (HyClone, Hudson, NH). Mycoplasma testing was performed every 6 months, in accordance with the manufacturer's protocol (Lonza, Rockland, ME).
RNA extraction and microarray expression analysis.
RNA from 41 OVCA cell lines was extracted using the RNeasy kit following manufacturer's recommendations (Qiagen, Valencia, CA). Quality of the RNA was measured using an Agilent 2100 Bioanalyzer. The targets for Affymetrix DNA microarray analysis were prepared according to the manufacturer's instructions, and targets were hybridized to customized Human Affymetrix HuRSTA gene chips (HuRSTA-2a520709), which include 60,607 probe sets and representation of 19,308 genes (Gene Expression Omnibus accession number GSE34615).
CellTiter-Blue cell viability assays. Drug activity was evaluated using a high-throughput CellTiter-Blue cell viability assay. Cells (2.5x10 3 per well) were plated in 384-well plates using complete media with 10% fetal bovine serum and allowed to adhere overnight. After cell adherence, increasing concentrations of gemcitabine were added to appropriate wells using an automated pipetting station. Building signatures of pathway activity. The principal component analysis (PCA) methodology was used to derive a gene expression signature for each pathway. A corresponding 'pathway score' was thus generated that quantifies the overall level of pathway gene expression in a summary value. That is, the PCA score is a numeric value that summarizes the level of expression of the entire pathway. First, data were reduced into a small set of uncorrelated principal components. This set of principal components was generated based on its ability to account for variation. The first PCA was used to represent the overall expression level for the pathway as it accounts for the largest variability in the data. That is, the pathway score is equal to ∑w i x i , a weighted average expression among the pathway genes, where x i represents gene i expression level, w i is the corresponding weight (loading coefficient) with ∑w 2 i =1, and the w i values maximize the variance of ∑w i x i . Details of this metho dology have been previously reported by our group (15, 16) .
Validation of signatures in primary OVCA datasets. The pathway gene expression signature scores were evaluated in an independent publicly available clinico-genomic dataset from 142 OVCA samples (16) . In brief, all 142 samples were known to have been resected from patients with advanced-stage (III/IV), serous epithelial OVCA, who underwent primary cytoreductive surgery followed by primary therapy with a platinum-based regimen (+/-taxane or cyclophosphamide). Response to this primary therapy [complete response (CR) versus incomplete response (IR)] has previously been described for these patients (16) . In brief, patients who demonstrated a CR had no evidence of disease on physical examination, serum tumor marker monitoring, or radiographic imaging. The IR category included all other patients. Log-rank tests with Kaplan-Meier survival curves were used to test any association between the pathway scores ('high' versus 'low' based on a median value cut-off) and overall survival for patients with OVCA. (Table I ). Pearson's correlation test using gemcitabine IC 50 and OVCA cell line gene expression data identified 131 unique genes to be associated with gemcitabine sensitivity (p<0.001; Table II) . GeneGo MetaCore™ analysis identified three biological pathways that were represented within the 131 genes associated with gemcitabine sensitivity (p<0.02). These molecular signaling pathways included O-glycan biosynthesis (p=0.001), Role of Nek in cell cycle regulation (p=0.005), and Antiviral actions of Interferons (p=0.01). Statistical significance was derived from the total number of genes input into the pathway analysis software, the number of input genes present in a specific pathway, and the actual number of genes in that pathway. Thus, the p-value represents the probability that mapping a set of genes to a particular pathway occurs by chance. The O-glycan pathway demonstrated the highest level of statistical significance in its association with sensitivity to gemcitabine (p=0.001) (Fig. 1) .
Results
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clinical outcome. Based on the above findings, we utilized PCA to develop gene expression signature scores for the pathways associated with gemcitabine sensitivity in vitro (15) . In this way, a 34-gene 'O-glycan biosynthesis pathway signature' (OGBPS) ( Table III) was generated and evaluated in an independent OVCA genomic dataset (16) . Using the median value as a threshold to define high versus low OGBPS score, we identified an association between high OGBPS score and favorable survival (p=0.003; Fig. 2A) . A similar association between high OGBPS score and favorable survival was observed in patients who underwent optimal (p=0.002) and suboptimal (approaching significance, p=0.07) cytoreduction (Fig. 2B ). Most importantly, OVCA patients with a high OGBPS score who underwent suboptimal cytoreduction had a survival superior to patients with a low OGBPS score who underwent optimal cytoreduction (p=0.003). Interestingly, patients who demonstrated a CR to primary platinum-based therapy but had a high OGBPS score had superior survival compared with those patients who demonstrated a CR but had a low OGBPS score (p=0.003) (Fig. 2C) . Patients who had an IR to primary therapy had no difference in survival associated with tumor OGBPS score (p= 0.653) (Fig. 2D ). When evaluated with cytoreductive status, grade, and age, the OGBPS score was an independent variable associated with survival (p<0.001).
No associations with survival were observed for the first PCA score for the Role of Nek in cell cycle regulation (59 genes, p=0.3107) or the Antiviral actions of Interferons pathway (66 genes, p=0.5411).
Discussion
In this analysis, we applied an in vitro and in vivo genome-wide approach to define the molecular underpinnings of OVCA gemcitabine sensitivity. We identified genes and molecular signaling pathways associated with OVCA sensitivity to gemcitabine and, in doing so, have identified the OGBPS to be associated with in vitro gemcitabine response and also overall survival from OVCA. Previous efforts to define the molecular basis of gemcitabine resistance have identified molecules such as deoxycytidine kinase (dCK) (8, (17) (18) (19) , ribonucleotide reductase (20) (21) (22) , and human equilibrative nucleoside transporter-1 (hENT1) (4, (23) (24) (25) (26) . Decreased activity of dCK, which phosphorylates gemcitabine to its monophosphate form, has previously been reported to be associated with resistance to gemcitabine (8, (17) (18) (19) . Consistent with these data, in our analysis, we demonstrated a negative correlation between OVCA cell line mRNA expression of the dCK gene and increasing gemcitabine resistance (Pearson's correlation: -0.33, p= 0.05). Previously, overexpression of the M1 and M2 subunits of ribonucleotide reductase (RRM1 and RRM2) has been demonstrated to be associated with gemcitabine resistance in gastrointestinal cancer cells (27, 28) . In our analysis, we observed no association between gemcitabine resistance and expression of RRM1, although we observed an association between low levels of RRM2 expression (using median expression as a threshold) and high gemcitabine IC 50 (p<0.02). It is unclear why our findings are contradictory to those of Davidson et al (27) ; however, they may be due to differences in cancer types studied. Inhibition of hENT1 was previously reported to be associated with gemcitabine chemoresistance (4, 25) . This correlates with our findings in which we demonstrated a negative correlation between OVCA cell line mRNA expression of the The process of glycosylation involves the enzymatic addition of carbohydrates to proteins or lipids and is the most common form of post-translational modification. Three categories of protein-linked glycans exist, including those linked to the amide group of asparagine (N-linked), those linked to the hydroxyl group of serine, threonine, or hydroxylysine 3 (O-linked), and those linked to a carboxyl group of tryptophan (C-linked) (29) . The main pathway for complex O-glycan biosynthesis is located in the endoplasmic reticulum and Golgi compartments, restricting glycosylation largely to the endoplasmic reticulum, Golgi, lysosomal, plasma membrane, and secretory proteins, with the exception of nuclear and cytosolic proteins, which can be modified with a single O-linked GlcNAc (30) . O-glycans have been reported to have a broad range of functions in protein structure and stability, immunity, receptor-mediated signaling, non-specific protein interactions, modulation of the activity of enzymes and signaling molecules, and protein expression and processing (30, 31) . Although these biological roles range in importance, they can be critical for development, growth, function, and survival. Moreover, a specific O-glycan may influence a range of functions at different locations and times within an organism (31) . Previously, limited access to endoglycosidases to cleave intact O-glycans from their protein backbone, as well as the extreme diversity of their structures, has limited research relative to study of N-linked glycan pathway-linked diseases (historically considered the congenital disorders of (36) . Down-regulation of the N-glycan biosynthesis pathway was also reported to be associated with chemoresistance in cholangiocarcinoma cell lines (37) .
To date, we are unaware of any reports suggesting that the O-glycan pathway influences OVCA cell response to therapeutic interventions or overall survival. In this study, expression of the O-glycan pathway (quantified by a OGBPS score) was associated with OVCA overall survival when we analyzed: a) all patients with OVCA, b) patients who underwent optimal OVCA surgical cytoreduction, and c) patients who experienced a CR to primary surgery plus platinum-based therapy. The association between OGBPS score and overall survival for patients who underwent suboptimal surgical cytoreduction did not reach statistical significance (p=0.07), and no association was identified in patients who experienced an IR to primary surgery plus platinum-based therapy. When evaluated with cytoreductive status, grade, and age, the OGBPS score was an independent variable associated with survival (p<0.001). The explanation for the associations between OGBPS and OVCA survival is likely complex. Although in this study we identified the O-glycan pathway by its association with in vitro gemcitabine sensitivity, we do not believe that the impact of the pathway on overall survival is driven by its effect of gemcitabine sensitivity. In fact, high OGBPS score was associated with resistance to gemcitabine, yet showed a more favorable outcome for patients with OVCA. As noted above, O-glycans are known to influence cancer cell attachment, signaling, invasion, and survival in the bloodstream (32) (33) (34) (35) . It is likely that the effect on OVCA clinical outcome is associated with one or more of these important oncologic processes. It will therefore be essential in future studies to investigate associations between OGBPS score, activity of individual members of the O-glycan pathway, and OVCA cell phenotypic behavior.
Our discovery of associations between O-glycan pathway expression and gemcitabine sensitivity and patient survival is novel. These findings potentially have substantial implications for future clinical management of patients with OVCA. In the future, empiric-based treatment decision-making must be replaced with a more tailored strategy that stratifies patients based on their molecular fingerprints. Such an approach will identify those patients with the 'highest risk' disease, those who may benefit from additional pathway-targeted therapy added to standard of care cytotoxic regimens, and potentially those who may (or may not) benefit from aggressive surgical interventions.
